Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2008

View Archived Issues

Jerini and PR collaborate on sustained-release formulations of ophthalmic drugs

BiPar Sciences expands clinical program for BSI-201 into glioblastoma multiforme

Preclinical activity of ENMD-2076 described

Galderma acquires CollaGenex

European Commission approves Effentora for breakthrough cancer pain

ChemGenex to submit rolling NDA to the FDA for omacetaxine mepesuccinate in CML

Lpath submits IND application to FDA for iSONEP in age-related macular degeneration

Jazz Pharmaceuticals' Luvox now available in the U.S. for treatment of SAD and OCD

Johnson & Johnson submits supplemental NDA for Risperdal Consta in FRBD

Isis reports additional results from phase II study of mipomersen in familial hypercholesterolemia

Medgenics to initiate phase I/II clinical trials in Israel of Epodure in anemia

Tolfenamic acid active against pancreatic cancer cells and tumors

H3 antagonists developed at Wyeth for cognitive dysfunction

Hdm2 antagonist JNJ-26854165 shows in vivo antitumor activity

Novel oral calcium receptor antagonists demonstrate bone formation activity in initial studies

HHS clears Iomai to begin phase II study of H5N1 adjuvant patch

FDA awards orphan drug designation for Rhitol in chronic GvHD

Silenor insomnia NDA accepted for filing

AnGes launches Naglazyme for mucopolysaccharidosis VI in Japan

Actemra approved in Japan to treat patients with rheumatoid arthritis

Humira approved in Japan for the treatment of rheumatoid arthritis

New therapeutic option for glaucoma reported in recent Organon patent

Recent Janssen patent discloses new therapeutic agents for benign prostatic hyperplasia

Recent Pfizer and Kyorin patents describe new agents for treating respiratory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...